You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Around the Region

Alnylam, Genzyme form alliance

Alnylam Pharmaceuticals Inc. and Genzyme, both of Cambridge, said Monday that they have formed an exclusive alliance to develop and commercialize RNAi therapeutics for the treatment of transthyretin-mediated amyloidosis, or ATTR, in Japan and other Asia-Pacific countries.

ATTR is a rare, debilitating, hereditary disease that damages the nervous system and heart, resulting in a life expectancy of 5 to 15 years.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week